2025年9月20日，淮安市清江浦区迎来一场瞩目的生物大健康产业盛事——华夏源(淮安)细胞药研发生 产基地开工仪式隆重举行。随着第一锹热土培下，这项总投资10亿元、占地32.51亩的战略性项目正式 驶入建设快车道，为淮安乃至长三角注入澎湃的"细胞动能"。 △ 清江浦区领导与华夏源共同为新基地培土 华夏源细胞集团成立于2015年，拥有以科学家、临床学者、药品申报专家为核心的管理团队，和以三位 诺贝尔奖获得者为核心的世界级科学顾问委员会。集团已获得国家436项专利著作权审批，在细胞治 疗、细胞级生物资源存储、干细胞新药研发、肿瘤类器官药筛服务等多领域具备核心竞争力。 政企同心，运河畔崛起细胞科技地标 清江浦区委书记赵洪涛出席并宣布项目正式开工，区长印祺热情致辞，区领导王磊、张晓宇，华夏源细 胞集团相关负责人及建设单位代表共同为项目奠基培土。政企"双向奔赴"的合力，让项目从签约到开工 按下"加速键"，为淮安生物技术与大健康产业写下浓墨重彩的一笔，为区域经济高质量发展提供重要支 撑。 △ 清江浦区委书记赵洪涛(左)宣布项目正式开工，区长印祺(中)热情致辞 沃土之上，淮安基地产业生态欣欣向荣 江苏淮安市被誉为"运河之都 ...

Core Viewpoint - The company, Kaineng Health, is entering the cell industry by establishing a wholly-owned subsidiary, Kaineng Cell Medical Group, with an investment of 100 million yuan, aiming to create a second growth curve through this strategic move [1][2]. Group 1: Business Expansion - Kaineng Health plans to focus on the cell and biotechnology sectors, covering areas such as medical aesthetics, medical research, drug clinical trials, and cosmetics production and sales [1][2]. - The establishment of the new subsidiary is part of the company's "dual energy drive" development strategy, aimed at strengthening its position in the cell industry and expanding its business footprint [2]. Group 2: Financial Performance - In the first half of 2025, Kaineng Health reported a revenue of 889 million yuan, a year-on-year increase of 7.23%, and a net profit attributable to shareholders of 70.15 million yuan, up 22.99% [1][2]. - The company's gross profit margin reached 41.12%, an increase of 0.62 percentage points compared to the same period last year, driven by improved production efficiency [2]. Group 3: Global Strategy - Kaineng Health is actively pursuing a "going global" strategy, establishing a comprehensive ecosystem and global layout across key markets in North America, Europe, and Asia-Pacific [3]. - The company has successfully expanded its water treatment products into over 100 countries and regions, with its Canadian subsidiary, Canature N.A.Inc., achieving a net profit of 23.97 million yuan in the reporting period [3]. Group 4: Industry Potential - The global cell therapy market is projected to exceed 30 billion USD by 2025, with a compound annual growth rate of over 20%, indicating significant growth potential for the company [4]. - Kaineng Health aims to leverage its existing water treatment business and the advantages of its partner, Yuaneng Group, in the cell industry to achieve synergistic development [5].

Core Viewpoint - JD.com is actively recruiting a head for its Cell Research Institute with a salary of one million, indicating its strategic focus on cell therapy as a significant breakthrough in the high-end medical services sector, with "cell storage" as a core business entry point [1][3][5]. Group 1 - The recruitment of a head for the Cell Research Institute has sparked discussions within the cell and gene therapy (CGT) industry [3]. - The job requirements highlight the need for experience in the commercialization of cell therapy products and practical experience with at least one CGT product's IND progress, suggesting JD.com's serious commitment to this field [5]. - JD.com has shown a strategic determination to deeply engage in the cell therapy sector, leveraging its strong financial resources, large user base, and e-commerce platform traffic to potentially disrupt traditional industry competition [8].